We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

27 hedge funds and large institutions have $16.8M invested in Northwest Biotherapeutics, Inc. Common stock in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

88% more capital invested

Capital invested by funds: $8.95M → $16.8M (+$7.88M)

35% more funds holding

Funds holding: 2027 (+7)

16% more call options, than puts

Call options by funds: $135K | Put options by funds: $116K

Holders
27
Holders Change
+7
Holders Change %
+35%
% of All Funds
0.88%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
7
Reduced
3
Closed
2
Calls
$135K
Puts
$116K
Net Calls
+$19K
Net Calls Change
-$22K
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
26
Jane Street
New York
-$87K -26,145 Closed
PSUF
27
People's United Financial
Connecticut
+$435 +125 New

NWBO Hedge Fund Activity: Q3 2013 in Review

27 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2013, worth a combined $16.8M — up 88% from $8.95M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NWBO positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $7.57M. The largest seller was Whitebox Advisors, cutting an estimated $1.67M.

  • 27 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2013, up from 20 in Q2 2013.
  • Funds reported $16.8M of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2013, up 88% quarter-over-quarter.
  • 9 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2013 and 2 closed out, a net change of +7 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2013 was Franklin Resources, an estimated $7.57M added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2013 was Whitebox Advisors, an estimated $1.67M sold.

Based on aggregated 13F filings for Q3 2013.